case_images: PMC9355247_01
case_images: Representative images of gastrointestinal bleeding and exacerbation of varicose veins after atezolizumab plus bevacizumab treatment. (A) Patients that developed gastrointestinal bleeding after treatment with atezolizumab plus bevacizumab. (B) Patients in which varices exacerbated during atezolizumab plus bevacizumab treatment. AB, atezolizumab plus bevacizumab treatment.
case_images: fonc-12-948293-g002.jpg
case_images: PMC9355247_07_fonc-12-948293-g002.jpg
case_images: f2
case_images: EGD performed 3 weeks after treatment initiation revealed rapidly exacerbated esophageal varices [Li F3 Cb RC(-)], detected as Li F1 Cb RC(-) prior to the initiation of AB treatment ( Figure 2B ).
case_images: PMC9355247_02
case_images: PMC9355247_03
case_images: Representative images of gastrointestinal bleeding and exacerbation of varicose veins after atezolizumab plus bevacizumab treatment. (A) Patients that developed gastrointestinal bleeding after treatment with atezolizumab plus bevacizumab. (B) Patients in which varices exacerbated during atezolizumab plus bevacizumab treatment. AB, atezolizumab plus bevacizumab treatment.
case_images: fonc-12-948293-g002.jpg
case_images: PMC9355247_07_fonc-12-948293-g002.jpg
case_images: f2
case_images: EGD performed 3 weeks after treatment initiation revealed rapidly exacerbated esophageal varices [Li F3 Cb RC(-)], detected as Li F1 Cb RC(-) prior to the initiation of AB treatment ( Figure 2B ).
case_images: PMC9355247_04
case_images: Representative images of gastrointestinal bleeding and exacerbation of varicose veins after atezolizumab plus bevacizumab treatment. (A) Patients that developed gastrointestinal bleeding after treatment with atezolizumab plus bevacizumab. (B) Patients in which varices exacerbated during atezolizumab plus bevacizumab treatment. AB, atezolizumab plus bevacizumab treatment.
case_images: fonc-12-948293-g002.jpg
case_images: PMC9355247_07_fonc-12-948293-g002.jpg
case_images: f2
case_images: EGD performed 3 weeks after treatment initiation revealed rapidly exacerbated esophageal varices [Li F3 Cb RC(-)], detected as Li F1 Cb RC(-) prior to the initiation of AB treatment ( Figure 2B ).
case_images: PMC9355247_05
case_images: PMC9355247_06
case_images: Representative images of gastrointestinal bleeding and exacerbation of varicose veins after atezolizumab plus bevacizumab treatment. (A) Patients that developed gastrointestinal bleeding after treatment with atezolizumab plus bevacizumab. (B) Patients in which varices exacerbated during atezolizumab plus bevacizumab treatment. AB, atezolizumab plus bevacizumab treatment.
case_images: fonc-12-948293-g002.jpg
case_images: PMC9355247_07_fonc-12-948293-g002.jpg
case_images: f2
case_images: EGD performed 3 weeks after treatment initiation revealed rapidly exacerbated esophageal varices [Li F3 Cb RC(-)], detected as Li F1 Cb RC(-) prior to the initiation of AB treatment ( Figure 2B ).
case_images: PMC9355247_07
case_images: Representative images of gastrointestinal bleeding and exacerbation of varicose veins after atezolizumab plus bevacizumab treatment. (A) Patients that developed gastrointestinal bleeding after treatment with atezolizumab plus bevacizumab. (B) Patients in which varices exacerbated during atezolizumab plus bevacizumab treatment. AB, atezolizumab plus bevacizumab treatment.
case_images: fonc-12-948293-g002.jpg
case_images: PMC9355247_07_fonc-12-948293-g002.jpg
case_images: f2
case_images: EGD performed 3 weeks after treatment initiation revealed rapidly exacerbated esophageal varices [Li F3 Cb RC(-)], detected as Li F1 Cb RC(-) prior to the initiation of AB treatment ( Figure 2B ).